15th Congress of the Asian Society of TransplantationRenal transplantationManagement of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study
Section snippets
Materials and Methods
We retrospectively retrieved 7 RTx patients in August 2015, who had been prescribed liraglutide with initial dose of 0.6 mg/day for 1 week adjusted every 0.6 mg weekly to optimal glycemic response upto maximal dose 1.8 mg/day due to poor glycemic control; however, 2 of them (28.6%) discontinued their scheduled doses within 1 month. One had nausea and vomiting, whereas the other had uncontrollable headaches, dizziness, and rhinorrhea. The initial renal function data were determined with serum
Benefits of Liraglutide in Diabetic RTx Recipients
The addition of liraglutide in diabetic RTx recipients improved sugar control through fasting blood sugar and HbA1c. It allowed for better graft renal function (Table 1). Although 4 patients (80%) had body weight (BW) reduction (range -2.1 to -3.0 kg) over a span of 10.5–27.6 months, 1 gained 8 kg during the management period of 17.3 months without a significant difference in BW control after liraglutide. The nadir BW (75.1 ± 9.1 kg) was a significant reduction from baseline BW (78.0 ± 7.8 kg; P
Discussion
ESRD patients nearly always recover their health and go on to experience a full life expectancy, along with a better quality of life after successful RTx. However, these patients continue to have higher morbidity and mortality rates (and their underlying diseases, particularly DM) than those in the general population, while also requiring long-term use of immunosuppressive agents. Chronic hyperglycemia has a detrimental cardiovascular effect as it triggers inflammatory responses and oxidative
References (13)
- et al.
Post-transplantation diabetes—state of the art
Lancet Diabetes Endocrinol
(2016) - et al.
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
Lancet Diabetes Endocrinol
(2018) - 2015 Annual Report on Kidney Disease in Taiwan....
- et al.
Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis
JAMA
(2016) - et al.
Treating post transplantation diabetes mellitus
Expert Opin Pharmacother
(2015) - et al.
Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes
Endocr Rev
(2016)
Cited by (35)
Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review
2023, Nutrition, Metabolism and Cardiovascular DiseasesManagement of new onset dysglycemia in transplant recipients
2023, Metabolic Syndrome: From Mechanisms to InterventionsInstitutional Experience With New Antidiabetic Drugs in Kidney Transplant
2021, Transplantation ProceedingsNovel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation
2021, Advances in Chronic Kidney DiseaseCitation Excerpt :Liraglutide in kidney transplant recipients resulted in significant body weight reduction and a trend toward better glucose control, and a reduction in HgbA1C.44,45 The addition of GLP-1RA to other antidiabetic agents, resulted in significantly reduced HgbA1C (10.04% to 8.14%, P = 0.047).44 Liraglutide has been compared to dulaglutide in a retrospective study by Singh and colleagues.
Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: A systematic review and meta-analysis
2021, Diabetes Research and Clinical PracticeCitation Excerpt :The mean patient follow-up in all the included in our analysis was 22.03 ± 14.95 weeks (median IQR: 23 (12–30.4). The difference of HbA1c before and after the administration of antidiabetics was reported in 15 trials [30–43] (Fig. 2). The range of difference between the mean values of HbA1c after and before treatment (MD) was between −3.49 to 1.14 with a confidence interval of 95%.
This study was supported by a grant from Taichung Veterans General Hospital (TCVGH-1077302B and TCVGH-1077302B), Taichung, Taiwan.